Creatine kinase isoenzyme (CK-BB) by RIA as a follow-up marker in stage D cancer of the prostate: comparison with PAP RIA

Fifty-nine patients with stage D carcinoma of the prostate under different modalities of treatment were studied for creatine phosphokinase isoenzyme BB (CK-BB) and prostatic acid phosphatase (PAP) levels in serum by radioimmunoassay (RIA) technique, in order to study the possible use of CK-BB as a follow-up marker compared to PAP. Thirty-three patients were in stable, 19 in progressive, and seven in regressive clinical state. CK-BB was above normal level in 52 (88%) out of 59 patients with no statistically significant difference between the three clinical states. On the other hand, PAP was above normal level in only 23 patients (38.98%) with statistically significant difference between the three clinical states (P less than 0.001). The PAP/CK-BB index was below 1 in stable and regressive condition, while it was above 1 in eight out of 19 patients with progressive disease. The PAP/CK-BB index may be of prognostic importance. CK-BB by RIA was abnormal in more cases than PAP. In this way CK-BB reflects the presence of the tumor and may be used for diagnosis; however, it does not reflect the clinical response as PAP does.     

Cellular localization of aldolase C subunits in human brain

An antiserum specific for the brain-type aldolase C subunit has been used to investigate the cellular localization of this protein in human brain. Immunoperoxidase labeling at the light microscope level showed heavy staining of Purkinje cells in the cerebellum and of astrocytes in the cerebrum. Faint staining of occasional large neurons in the gray matter of the cerebral cortex was also seen.     

血清GPDA同工酶对原发性肝癌的诊断价值

对５５例原发性肝癌，６６例其他肝病，１６例肝外肿瘤和２２名正常人，应用自行设计的聚丙烯酰胺凝胶阶段梯度电泳作ＧＰＤＡ同工酶检测，将血清ＧＰＤＡ分离出１０条同工酶区带。结果发现血清ＧＰＤＡⅡ／Ⅱ’在ＰＨＣ中的阳性率为４１．８％，而在非癌性肝病和肝外肿瘤患者中阳性率均很低，在正常对照组中全部阴性，其对ＰＬＣ诊断敏感性为４１．８％，特异性为８９％。ＡＦＰ阳性与阴性的ＰＨＣ，以及小肝癌与中晚期肝癌患者，血     

精神分裂症患者血清肌酸激酶及其同工酶的检测分析

目的探讨血清肌酸激酶及其同工酶与精神分裂症的关系.方法使用速率法(CK)和免疫抑制法(CKMB)检测60例精神分裂症患者及本院40例健康职工血清中CK、CKMB水平.结果精神分裂症患者入院时血清CK、CKMB水平较出院时、对照组都高,差异有显著性(P<0.01).结论随着精神分裂症患者病情得到控制,其血清CK、CKMB水平亦趋于正常,血清肌酸激酶及其同工酶测定在精神分裂症治疗中具有重要的参考价值.     

心肌标志物在诊断急性心肌梗死中的临床应用及诊断临界值分析

目的探讨心肌标志物肌红蛋白(MYO)、肌酸激酶同工酶MB(CK-MB)、超敏肌钙蛋白I(TnI-Ultra)对急性心肌梗死(AMI)的临床诊断价值,并确立其临床诊断临界值。方法回顾性分析本院377例患者心肌标志物的检测结果,并将划分为6组,比较AMI组与其他各组的差异,同时应用受试者工作特征(ROC)曲线评估其临床诊断临界值。结果 AMI组除MYO与肺部疾病组差异无统计学意义(P>0.05)外,MYO、CK-MB、TnI-Ultra与其他各组比较差异均有统计学意义(P<0.01)。ROC曲线显示MYO、CK-MB、TnI-Ultra的临床诊断临界值分别为102.4、5.99、0.273ng/mL,其ROC曲线下面积(AUC)分别为0.781、0.900、0.992。结论心肌标志物在AMI诊断中具有重要的临床价值,各临床实验室应该根据各自的检测条件确立适当的临床诊断临界值。     

急性重度CO中毒心肌损害患者高压氧治疗期间血清相关酶的变化及意义

目的观察重度急性一氧化碳中毒(ACOP)后心肌损害患者高压氧(HBO)治疗期间血清肌酸激酶(CK)及其心型同工酶(CK-MB)的变化,探讨HBO治疗CO中毒心肌损害的机理、疗效以及治疗过程中血清CK、CK-MB定量检测的临床意义.方法对32例Glasgow评分3～7分的重度ACOP患者分别在HBO治疗1、3、5、10次后测定其血清CK、CK-MB含量,并对患者进行同步心电图(ECG)检查.另外在健康体检中随机选取30例健康人血清标本,分别测定其血清CK、CK-MB作为对照组.结果随着HBO治疗次数的增多,患者ECG逐渐恢复正常,血清CK、CK-MB含量显著下降(P<0.01).结论经HBO治疗,重度ACOP患者的心肌损害可以较快地得到恢复.血清CK、CK-MB检测结合ECG可以在治疗中动态地了解心肌损害的程度和恢复情况.     

Creatine kinase* isoenzyme patterns in Duchenne muscular dystrophy

Serum creatine kinase isoenzymes were studied in 41 patients suffering from Duchenne type muscular dystrophy and 20 mothers of patients (carriers) by cellulose acetate electrophoresis. Both the MM and MB types were found in all cases of Duchenne type dystrophy patients, and in carriers with highly elevated total creatine kinase activity BB was not observed above the detection limits of the methods used. However, a so-called atypical CK-BB band has been demonstrated.     

PCT联合心脏相关标志物对脓毒症患儿病情的预测价值

目的 探讨降钙素原(PCT)联合心脏相关标志物检测在脓毒症患儿病情预测中的价值.方法 选取脓毒症患儿132例,其中早期脓毒症患儿87例(早期脓毒症组),严重脓毒症患儿45例(严重脓毒症组),检测患儿PCT、肌酸激酶同工酶(CK-MB)、超敏肌钙蛋白T(cTnT-hs)和氨基末端脑钠肽前体(NT-proBNP)水平.结果 早期脓毒症组和严重脓毒症组患儿性别、年龄以及感染部位分布比较,差异无统计学意义(P>0櫃.05);严重脓毒症组PCT、CK-MB、cTnT-hs和NT-proBNP明显高于早期脓毒症组(P<0.05);PCT、CK-MB、cTnT-hs、NT-proBNP预测严重脓毒症的ROC曲线下面积分别为0.982、0.880、0.730和0.947,灵敏度分别为90.03%、68.90%、46.70%和84.63%.将PCT与CK-MB、cTnT-hs和NT-proBNP联合诊断严重脓毒症,其诊断灵敏度为97.80%,高于各指标单独使用时.结论 PCT联合心脏相关标志物检测在脓毒症患儿病情预测中有较高的应用价值,值得进一步研究.     

蛋白酶抑制剂联合CRRT对脓毒症患者FABP3、GPBB水平的影响

目的 探讨蛋白酶抑制剂联合连续肾脏代替治疗(CRRT)对脓毒症患者心型脂肪酸结合蛋白(FABP3)、糖原磷酸化酶同工酶BB(GPBB)水平的影响。方法 选取2019年2月至2020年6月我院收治的脓毒症患者134例,按照随机数字表法分为CRRT组与联合治疗组,每组各67例。其中CRRT组患者进行CRRT治疗,联合治疗组患者进行CRRT联合蛋白酶抑制剂进行治疗。使用流式细胞仪对CD4+、CD8+、CD4+/CD8+指标水平进行测定与比较,采用酶联免疫法检测白介素-8(IL-8)、肿瘤细胞因子-α(TNF-α)、白介素-6(IL-6)及脂肪酸结合蛋白3(FABP3)、糖原磷酸化酶同工酶BB(GPBB)水平,并比较,免疫组化法检测D-乳酸、二胺氧化酶(DAO)水平,并对两组患者治疗疗效进行评价。结果 治疗后,与CRRT组相比,联合治疗组CD4+指标水平与CD4+/CD8+均较高,CD8+指标水平较低(P0.05);与CRRT组相比,联合治疗组IL-8、TNF-α、IL-6水平均较低(P0.05);联合治疗组D-乳酸水平及DAO水平均低于CRRT组(P0.05);与CRRT组相比,联合治疗组FABP3水平较高、GPBB水平较低(P0.05);与CRRT组相比,联合治疗组治疗总有效率较高(P0.05)。结论 使用蛋白酶抑制剂联合CRRT对脓毒症患者进行治疗,能够显著改善患者免疫功能,抑制炎症反应,同时能够降低肠道黏膜损害程度,使得FABP3水平升高、GPBB水平降低,从而减轻脓毒症患者心肌损伤程度。